Nitroglycerin

also known as glyceryl trinitrate · GTN · NTG · MQX-503 · Rectogesic · nitroglycerine · Nitroglycerin tablets · Nitrostat · +15 more

Developed for: coronary artery disorder · Raynaud disease · non-small cell lung carcinoma · erectile dysfunction · hypertensive disorder · heart failure · hypotensive disorder · intracerebral hemorrhage
+54 more
· ischemic stroke · acute kidney injury · arterial disorder · autonomic dysreflexia · chronic obstructive pulmonary disease · chronic ulcer of skin · coronary vasospasm · COVID-19 · diabetic neuropathy · disease of bone structure · end stage renal failure · esophageal disorder · female infertility · infectious disease with sepsis · ischemic disease · left ventricular failure · lung cancer · metastatic malignant neoplasm in the brain · myocardial disorder · myocardial infarction · myocardial ischemia · myofascial pain syndrome · nosocomial infection · obstructive sleep apnea syndrome · osteoporosis · pancreatitis · periodontal disorder · peripheral arterial disease · phlebitis · placenta disorder · preeclampsia · prosthesis-related infectious disease · pulmonary arterial hypertension · pulmonary edema · rectal cancer · scleroderma · sickle cell disease · symptomatic heart failure · tendinitis · ulcer of anus and rectum · acute myocardial infarction · acute pancreatitis · acute tubulointerstitial nephritis · arterial occlusion · breast disorder · disease of the tendon · intracranial vasospasm · nonobstructive coronary artery disease · pregnancy disorder · pulmonary hypertension · pulmonary hypertension, neonatal · rectal disorder · ST-elevation myocardial infarction · stroke disorder
Investigated by: MediQuest Therapeutics · National Heart, Lung, and Blood Institute (NHLBI) · University of California, San Francisco · Vanderbilt University · Assiut University · Danish Headache Center
+86 more
· Seoul National University Hospital · Bayer · Futura Medical Developments Ltd. · Instituto de Cardiologia de Santa Catarina · Minia University · Thomas Jefferson University · University of Edinburgh · 424 General Military Hospital · Aarhus University Hospital · Ain Shams University · Alison Huang, MD · Anticancer Fund, Belgium · Aristotle University Of Thessaloniki · Augusta University · Beni-Suef University · Bristol-Myers Squibb · Cairo University · Copenhagen University Hospital, Hvidovre · Covis Pharma S.à.r.l. · Cure Therapeutics · Deborah Heart and Lung Center · Duke University · Dutch Society of Physicians for Pulmonology and Tuberculosis · EUROHEAD · Erasmus Medical Center · First Affiliated Hospital of Wannan Medical College · Forest Laboratories · Frisius Medisch Centrum · GF Strong Rehabilitation Centre · HealthPartners Institute · Hospital General Universitario Elche · Icahn School of Medicine at Mount Sinai · Indiana University · Instituto Nacional de Cardiologia Ignacio Chavez · Johns Hopkins University · King Edward Medical University · King's College London · Kolding Sygehus · Komar University of Science and Technology · Kyoto University · Liang Bing · M.D. Anderson Cancer Center · Maastricht Radiation Oncology · Mansoura University · Merck Sharp & Dohme LLC · Mohammad Ali Nazarinia · Muhammad Aamir Latif · NHS Lothian · Nanjing First Hospital, Nanjing Medical University · National Cancer Institute of Mexico · National Center for Research Resources (NCRR) · National Cheng-Kung University Hospital · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Cancerology · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute on Aging (NIA) · National Institutes of Health Clinical Center (CC) · Novel Anti-Infective Technologies, LLC · Orthopaedic Trauma Association · Pfizer · Procris Pharmaceuticals · Rabin Medical Center · Reliable Cancer Therapies · Richmond Pharmacology Limited · Shiraz University of Medical Sciences · Simon Fraser University · South London and Maudsley NHS Foundation Trust · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Tri-Service General Hospital (TSGH) · US Department of Veterans Affairs · University College London Hospitals · University College, London · University Hospital Birmingham · University Hospital, Basel, Switzerland · all 92 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	NITROLINGUAL	—	1997-01-10	fda.gov ↗
Approved	US (FDA)	NITROGLYCERIN	—	1981-05-28	fda.gov ↗

Trials 93 · started per year

today

US approved 1981

1981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05239013	May 2022 → Mar 2023	arterial disorder	Thomas Jefferson University	Unknown	No outcome recorded
Phase 0	NCT06172998	Apr 2022 → Apr 2024	obstructive sleep apnea syndrome	Xu J	Unknown	No outcome recorded
Phase 0	NCT04155476	Dec 2019 → Mar 2020	peripheral arterial disease	Deborah Heart and Lung Center	Unknown	No outcome recorded
Phase 19 trials · 1 met primary
Phase 1	NCT07431294	Jan → May 2027 expected	coronary artery disorder	Bayer	Not yet recruiting	No outcome recorded
Phase 1	NCT07004764	Nov 2026 → Sep 2027 expected	—	Johns Hopkins University	Not yet recruiting	No outcome recorded
Phase 1	NCT04008732	Nov 2017 → Apr 2018	erectile dysfunction	Futura Medical Developments Ltd.	Completed	No outcome recorded
Phase 1	NCT02617550	Nov 2015 → May 2016	coronary artery disorder	Bayer	Completed	No outcome recorded
Phase 1	NCT02425566	Apr 2015 → Jul 2026 overdue	hypertensive disorder	Vanderbilt University	Active not recruiting	No outcome recorded
Phase 1	NCT01407107	Jan 2011 → Oct 2015	rectal cancer	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 1	NCT00686231	May → Dec 2008	—	University of California, San Francisco	Completed	Met primary
Phase 1	NCT01616485	Mar → May 2004	erectile dysfunction	VIVUS LLC	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT05442931	May → Oct 2022	—	Minia University	Unknown	No outcome recorded
Phase 1/2	NCT04685031	Feb → Apr 2021	phlebitis	Komar University of Science and Technology	Unknown	No outcome recorded
Phase 1/2	NCT02577718	Nov 2015 → Jun 2016	nosocomial infection, prosthesis-related infectious disease	Novel Anti-Infective Technologies, LLC	Completed	No outcome recorded
Phase 221 trials · 1 met primary · 3 missed
Phase 2	NCT05635851	Dec 2026 → Feb 2028 expected	autonomic dysreflexia, spinal cord injury	Simon Fraser University	Not yet recruiting	No outcome recorded
Phase 2	NCT07682454	Aug 2026 → Feb 2029 expected	hepatocellular carcinoma	University of California, San Francisco	Not yet recruiting	No outcome recorded
Phase 2	NCT06289946	Mar 2024 → Mar 2025	coronary artery disorder	Thomas Jefferson University	Unknown	No outcome recorded
Phase 2	NCT03259165	Dec 2017 → Dec 2021	heart failure, pulmonary edema	Indiana University	Terminated	No outcome recorded
Phase 2	NCT03357731	Nov 2017 → May 2019	left ventricular failure	Bristol-Myers Squibb	Completed	Missed primary
Phase 2	NCT02714205	Apr 2017 → Mar 2022	—	Alison Huang, MD	Completed	Missed primary
Phase 2	NCT02801305	Jun 2016 → Jan 2017	chronic ulcer of skin	Mohammad Ali Nazarinia	Completed	No outcome recorded
Phase 2	NCT02688270	Jun → Dec 2016	Raynaud disease	Covis Pharma S.à.r.l.	Completed	No outcome recorded
Phase 2	NCT03235921	Mar 2016 → Aug 2017	—	Assiut University	Unknown	No outcome recorded
Phase 2	NCT02495467	May 2015 → Jul 2016	erectile dysfunction	Futura Medical Developments Ltd.	Completed	Met primary
Phase 2	NCT01811693	Apr → Sep 2013	intracerebral hemorrhage, ischemic stroke	University of California, Los Angeles	Terminated	No outcome recorded Stop: Business
Phase 2	NCT01210378	Dec 2011 → Sep 2016	non-small cell lung carcinoma	Maastricht Radiation Oncology	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01171170	Jan 2011 → Jun 2014	non-small cell lung carcinoma	Dutch Society of Physicians for Pulmonology and Tuberculosis	Completed	Missed primary
Phase 2	NCT02327793	Jun 2009 → Jul 2015	ischemic stroke	University of Alberta	Completed	No outcome recorded
Phase 2	NCT00616031	Jan 2008 → Dec 2011	lung cancer	Kyoto University	Unknown	No outcome recorded
Phase 2	NCT00641953	Aug 2007 → Mar 2008	diabetic neuropathy	Procris Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00480753	May → Aug 2007	Raynaud disease	MediQuest Therapeutics	Completed	No outcome recorded
Phase 2	NCT00447928	Apr → Nov 2007	tendinitis	Cure Therapeutics	Unknown	No outcome recorded
Phase 2	NCT00886405	Jul 2006 → Apr 2009	non-small cell lung carcinoma	National Institute of Cancerology	Unknown	No outcome recorded
Phase 2	NCT00090558	Aug 2004 → Sep 2005	coronary artery disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00001716	Jul 1998 → Jul 2003	intermediate coronary syndrome, sickle cell disease	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded

Phase 2/34 trials · 1 met primary
Phase 2/3	NCT06785337	Feb → Oct 2025 overdue	chronic obstructive pulmonary disease	Beni-Suef University	Recruiting	No outcome recorded
Phase 2/3	NCT01155167	Jul 2010 → Aug 2011	—	University of California, San Francisco	Completed	Met primary
Phase 2/3	NCT00253331	Nov 2004 → Sep 2005	Raynaud disease	MediQuest Therapeutics	Completed	No outcome recorded
Phase 2/3	NCT01279551	Jan 2004 → Sep 2010	—	University of Roma La Sapienza	Completed	No outcome recorded
Phase 311 trials · 1 met primary · 1 missed
Phase 3	NCT04766151	Jan → Dec 2021	coronary vasospasm	424 General Military Hospital	Unknown	No outcome recorded
Phase 3	NCT04321967	Aug 2019 → Nov 2022	gynecomastia disorder	Icahn School of Medicine at Mount Sinai	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT03158532	Jul 2017 → Oct 2021	—	Instituto de Cardiologia de Santa Catarina	Completed	No outcome recorded
Phase 3	NCT02343276	Feb → Aug 2015	—	Instituto de Cardiologia de Santa Catarina	Completed	No outcome recorded
Phase 3	NCT01864252	Jan 2014 → Oct 2018	myocardial disorder	University College, London	Completed	No outcome recorded
Phase 3	NCT01132391	Jan → Apr 2009	ulcer of anus and rectum	Hospital General Universitario Elche	Completed	Met primary
Phase 3	NCT00493415	Jun 2007 → Jul 2008	infectious disease with sepsis	Frisius Medisch Centrum	Completed	Missed primary
Phase 3	NCT00419419	Dec 2006 → ?	Raynaud disease, scleroderma	MediQuest Therapeutics	Completed	No outcome recorded
Phase 3	NCT00266669	Dec 2005 → May 2006	Raynaud disease	MediQuest Therapeutics	Completed	No outcome recorded
Phase 3	NCT00043719	Jul 2002 → Dec 2007	osteoporosis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	No outcome recorded
Phase 3	NCT00000503	Aug 1982 → Oct 1987	coronary artery disorder, myocardial infarction, myocardial ischemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 417 trials · 1 met primary · 2 missed
Phase 4	NCT07391501	Feb 2026 → Nov 2028 expected	internal hemorrhoid	Ying Zhu	Not yet recruiting	No outcome recorded
Phase 4	NCT07044232	Oct 2025 → Sep 2026 overdue	intracerebral hemorrhage	Aarhus University Hospital	Recruiting	No outcome recorded
Phase 4	NCT07083063	Sep 2025 → Jul 2027 expected	pancreatitis	National Cheng-Kung University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06682260	Feb → Nov 2025	heart failure	Copenhagen University Hospital, Hvidovre	Completed	No outcome recorded
Phase 4	NCT05687669	Jan → Apr 2023	preeclampsia	Assiut University	Completed	No outcome recorded
Phase 4	NCT06428669	Aug 2022 → Aug 2025	—	University of Virginia	Unknown	No outcome recorded
Phase 4	NCT03809065	Jan → May 2019	hypotensive disorder	Cairo University	Completed	Met primary
Phase 4	NCT03777605	Dec 2018 → Dec 2020	intermediate coronary syndrome	Kolding Sygehus	Unknown	No outcome recorded
Phase 4	NCT03304496	Mar 2018 → Mar 2019	coronary artery disorder	Instituto Nacional de Cardiologia Ignacio Chavez	Suspended	No outcome recorded
Phase 4	NCT03305848	Aug 2017 → Apr 2019	esophageal disorder	HealthPartners Institute	Completed	No outcome recorded
Phase 4	NCT02708251	Oct 2016 → May 2017	—	Assiut University	Completed	No outcome recorded
Phase 4	NCT02265965	Oct 2015 → Jul 2018	—	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT02085213	Sep 2014 → Jul 2017	placenta disorder	University of Edinburgh	Completed	No outcome recorded
Phase 4	NCT01920074	Jun 2013 → Mar 2015	—	Forest Laboratories	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01685710	Apr 2013 → May 2015	kidney failure	University Hospital Birmingham	Completed	Missed primary
Phase 4	NCT00512759	Dec 2007 → Aug 2018	symptomatic heart failure	University Hospital, Basel, Switzerland	Completed	Missed primary
Phase 4	NCT00479908	Jan 2004 → Sep 2005	intermediate coronary syndrome	University of Edinburgh	Completed	No outcome recorded

Phase not applicable25 trials · 1 met primary · 3 missed
—	NCT07603037	Jul 2026 → Jul 2027 expected	acute respiratory failure, aortic disorder, hypertensive disorder	First Affiliated Hospital of Wannan Medical College	Not yet recruiting	No outcome recorded
—	NCT07159334	Aug → Dec 2025 overdue	hemorrhoid	King Edward Medical University	Recruiting	No outcome recorded
—	NCT06925763	Apr 2025 overdue	disease of bone structure, periodontal disorder	Minia University	Not yet recruiting	No outcome recorded
—	NCT06637956	Jan → Jun 2024	—	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT05855954	May 2023 → Aug 2025 overdue	acute kidney injury	Nanjing First Hospital, Nanjing Medical University	Recruiting	No outcome recorded
—	NCT06238882	Feb 2023 → Dec 2026 expected	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	National Cancer Institute of Mexico	Recruiting	No outcome recorded
—	NCT05443061	Sep 2022 → Mar 2025	ischemic disease	Seoul National University Hospital	Completed	Met primary
—	NCT07214129	Mar 2022 → Mar 2023	pulmonary arterial hypertension	Mansoura University	Completed	No outcome recorded
—	NCT04686760	Nov 2020 → Dec 2021	COVID-19	University of Lahore	Completed	No outcome recorded
—	NCT04564521	Sep 2020 → Jun 2024	retinoblastoma	Seoul National University Hospital	Unknown	No outcome recorded
—	NCT03917004	Apr → Sep 2019	hypotensive disorder	Liang Bing	Unknown	No outcome recorded
—	NCT03849183	Mar → Jul 2019	—	Seoul National University Hospital	Completed	No outcome recorded
—	NCT03481582	Nov 2017 → Mar 2018	female infertility, polycystic ovary syndrome	Ain Shams University	Completed	No outcome recorded
—	NCT02906553	Sep 2016 → Apr 2019	schizophrenia	King's College London	Completed	Missed primary
—	NCT02164318	Sep 2014 → Feb 2016	end stage renal failure	Duke University	Terminated	No outcome recorded Stop: Enrollment
—	NCT02115724	Apr 2014 → Dec 2026 expected	cardiovascular disorder	Augusta University	Active not recruiting	No outcome recorded
—	NCT02059018	Feb 2014 → Feb 2015	retinal ischemia	University of Aarhus	Completed	No outcome recorded
—	NCT01901419	Jul 2013 → Jun 2017	hyperglycemia, lactic acidosis	Tri-Service General Hospital (TSGH)	Completed	Missed primary
—	NCT01675700	Jan → Jul 2009	myofascial pain syndrome	GF Strong Rehabilitation Centre	Completed	No outcome recorded
—	NCT00838695	Jan 2009 → Dec 2010	—	Vanderbilt University	Completed	No outcome recorded
—	NCT00363571	Aug 2006 → May 2007	migraine disorder	Danish Headache Center	Unknown	No outcome recorded
—	NCT00375362	Jul → Sep 2006	—	Rabin Medical Center	Unknown	No outcome recorded
—	NCT00335010	May → Dec 2005	esophageal cancer	Erasmus Medical Center	Completed	Missed primary
—	NCT00257985	Apr 2005 → Mar 2006	familial hemiplegic migraine	Danish Headache Center	Completed	No outcome recorded
—	NCT00363792	? → May 2007	—	Danish Headache Center	Unknown	No outcome recorded

Comparator or background therapy72 trials
Phase 0	NCT03059316 Comparator	Jun 2016 → Apr 2017	—	Cairo University	Completed	No outcome recorded
Phase 0	NCT04017845 Comparator	Apr 2015 → May 2017	adenomatous colon polyp, colorectal cancer	Lewai Sharki Abdulaziz, MSc PhD	Completed	No outcome recorded
Phase 1	NCT04594629 Comparator	Nov 2020 → May 2021	pulmonary hypertension	Ain Shams University	Unknown	No outcome recorded
Phase 1	NCT00841594 Comparator	Feb 2009	Raynaud disease	MediQuest Therapeutics	Completed	No outcome recorded
Phase 1	NCT00700518 Comparator	Jun → Nov 2008	Raynaud disease	Procris Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00513994 Comparator	Aug → Oct 2007	—	MediQuest Therapeutics	Completed	No outcome recorded
Phase 1/2	NCT04220281 Comparator	Dec 2019 → Feb 2020	—	Ain Shams University	Terminated	No outcome recorded
Phase 2	NCT03478332 Comparator	Jun 2017 → May 2020	coronary artery disorder	Affiliated Hospital of Changchun University of Chinese Medicine	Unknown	No outcome recorded
Phase 2/3	NCT06107465 Comparator	Nov 2023 → Jun 2024	pulmonary edema	Alexandria University	Unknown	No outcome recorded
Phase 2/3	NCT03716050 Comparator	Jan 2018 → Mar 2019	—	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT00953303 Comparator	Jan 2009 → Sep 2011	heart failure	Hebei Medical University	Completed	No outcome recorded
Phase 2/3	NCT00419549 Comparator	Oct 2003 → Sep 2005	acute pancreatitis	All India Institute of Medical Sciences	Terminated	No outcome recorded
Phase 3	NCT06912139 Comparator	Apr → Jun 2023	coronary vasospasm	University of Medicine and Pharmacy "Victor Babes" Timisoara	Completed	No outcome recorded
Phase 3	NCT06301880 Comparator	Jan 2022 → Jan 2023	—	Damascus University	Completed	No outcome recorded
Phase 3	NCT05837403 Background	Oct 2020 → Jul 2022	ulcer of anus and rectum	Al-Kindy College of Medicine	Completed	No outcome recorded
Phase 3	NCT03689946 Background	Mar 2019 → Jan 2023	cardiovascular disorder, hyperlipidemia	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 3	NCT03787030 Comparator	Dec 2018 → Feb 2019	—	Hospital General Universitario Elche	Completed	Met primary
Phase 3	NCT03622060 Comparator	Jun 2018 → May 2019	arterial occlusion, isoproterenol-mediated vasodilatation, radial neuropathy	Hermina Heart Center Kemayoran	Completed	No outcome recorded
Phase 3	NCT02413268 Comparator	Mar 2016 → Jul 2020	arterial occlusion	Total Cardiovascular Solutions	Unknown	No outcome recorded
Phase 3	NCT02700438 Comparator	Jan 2014 → Jan 2016	—	Hospital General Universitario Elche	Completed	No outcome recorded
Phase 3	NCT01387672 Comparator	Sep 2011 → Dec 2014	osteoporosis	University of Toronto	Completed	No outcome recorded
Phase 3	NCT00934427 Comparator	Jun 2009 → Jun 2010	Raynaud disease	MediQuest Therapeutics	Unknown	No outcome recorded
Phase 3	NCT00803634 Comparator	Dec 2008 → Feb 2012	heart failure, hypertensive disorder	The Medicines Company	Completed	No outcome recorded
Phase 3	NCT00577304 Comparator	Dec 2007 → Mar 2008	Raynaud disease, scleroderma	MediQuest Therapeutics	Unknown	No outcome recorded
Phase 3	NCT00252421 Comparator	Oct 2005 → Jun 2010	osteoporosis	University of Toronto	Completed	No outcome recorded
Phase 3	NCT00093886 Comparator	Apr 2004 → Mar 2005	hypertensive disorder	The Medicines Company	Completed	No outcome recorded
Phase 3	NCT00989716 Comparator	Jul 2001 → Oct 2013	stroke disorder	University of Nottingham	Unknown	No outcome recorded
Phase 4	NCT06859554 Comparator	Mar → May 2025	anal spasm	Hafiz Muhammad Hamza	Completed	No outcome recorded
Phase 4	NCT05616455 Comparator	Oct 2021 → Mar 2022	ulcer of anus and rectum	Treviso Regional Hospital	Completed	No outcome recorded
Phase 4	NCT04661709 Background	Mar 2021 → Mar 2023	intermediate coronary syndrome	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT04270071 Background	Dec 2020 → Oct 2021	coronary artery disorder	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT04270279 Background	Dec 2020 → Aug 2021	coronary artery disorder	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT04355598 Comparator	Apr → Aug 2020	—	Cairo University	Unknown	No outcome recorded
Phase 4	NCT04002544 Comparator	Sep → Nov 2019	—	Cairo University	Completed	No outcome recorded
Phase 4	NCT04320498 Background	Jan → Dec 2019	ulcer of anus and rectum	KTO Karatay University	Completed	No outcome recorded
Phase 4	NCT03252665 Comparator	Sep 2017 → Jun 2019	ST-elevation myocardial infarction	RenJi Hospital	Unknown	Met primary
Phase 4	NCT03251599 Comparator	Aug → Nov 2017	—	Recep Tayyip Erdogan University	Completed	No outcome recorded
Phase 4	NCT02961946 Comparator	Mar → Oct 2017	coronary artery disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01996436 Comparator	Aug 2016 → Apr 2024	intracranial vasospasm	Peng Roc Chen, MD	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03296670 Comparator	Aug 2015 → Apr 2017	ST-elevation myocardial infarction, coronary artery disorder	RenJi Hospital	Completed	No outcome recorded
Phase 4	NCT02209636 Background	Sep 2014 → Jun 2019	cardiovascular disorder, chronic kidney disease	VA Office of Research and Development	Completed	Missed primary
Phase 4	NCT02583633 Comparator	Oct 2013 → Oct 2014	—	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT01999517 Comparator	Jun 2013 → Jun 2018	acute tubulointerstitial nephritis	Mt. Sinai Medical Center, Miami	Completed	No outcome recorded
Phase 4	NCT02254252 Comparator	Mar 2012 → Mar 2013	nonobstructive coronary artery disease	Mashhad University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT01502943 Background	May → Dec 2011	intermediate coronary syndrome	Liaoning University of Traditional Chinese Medicine	Completed	No outcome recorded
Phase 4	NCT00712894 Comparator	Dec 2006 → Apr 2009	acute myocardial infarction	Fudan University	Completed	Met primary
Phase 4	NCT00431691 Comparator	Sep 2006 → Dec 2007	escherichia coli infection, retinal disorder	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00842023 Comparator	Jul 2006 → Jul 2008	heart failure	Western University of Health Sciences	Completed	No outcome recorded
—	NCT05741229 Comparator	Jan → Dec 2024	pulmonary hypertension, neonatal, respiratory system disorder	Alexandria University	Completed	No outcome recorded
—	NCT05952011 Background	Aug 2023 → Feb 2025	—	Ain Shams University	Completed	No outcome recorded
—	NCT05718310 Comparator	Nov 2022 → Dec 2024	migraine disorder	IRCCS National Neurological Institute "C. Mondino" Foundation	Unknown	No outcome recorded
—	NCT05590520 Comparator	Nov 2022 → Nov 2023	ulcer of anus and rectum	Pak Emirates Military Hospital	Unknown	No outcome recorded
—	NCT07585201 Comparator	Sep 2022 → Feb 2023	hypotensive disorder	Zagazig University	Completed	No outcome recorded
—	NCT05682716 Background	Jul → Nov 2022	acute kidney injury	Nanjing First Hospital, Nanjing Medical University	Completed	No outcome recorded
—	NCT07074834 Background	Feb 2021 → Sep 2022	coronary artery disorder	Shiyan City Renmin Hospital	Completed	No outcome recorded
—	NCT04918563 Comparator	Sep 2020 → Apr 2021	mouth mucosa disorder	Semmelweis University	Completed	No outcome recorded
—	NCT03605095 Comparator	Jul → Aug 2018	mouth disorder	Semmelweis University	Completed	No outcome recorded
—	NCT03528772 Comparator	May 2018 → Aug 2019	—	Mansoura University	Completed	No outcome recorded
—	NCT03408054 Comparator	Jan → Apr 2018	—	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Completed	No outcome recorded
—	NCT03102502 Background	Mar 2017 → Oct 2018	coronary artery disorder	Sun Yat-sen University	Completed	No outcome recorded
—	NCT02499484 Comparator	Sep 2016 → Nov 2018	disease of the tendon	Royal College of Surgeons, Ireland	Completed	No outcome recorded
—	NCT04220606 Background	Apr 2015 → Apr 2016	migraine without aura	Leiden University Medical Center	Completed	No outcome recorded
—	NCT02105493 Comparator	Oct 2013 → Feb 2014	—	National Cardiovascular Center Harapan Kita Hospital Indonesia	Completed	No outcome recorded
—	NCT02083055 Comparator	Dec 2012 → Feb 2014	hypotensive disorder	Mahidol University	Completed	No outcome recorded
—	NCT01608880 Comparator	Aug 2012 → Mar 2014	breast disorder	University of British Columbia	Completed	No outcome recorded
—	NCT01490073 Comparator	Mar → Nov 2012	—	Oregon Health and Science University	Completed	No outcome recorded
—	NCT01212874 Comparator	Dec 2010 → Jun 2014	hypertensive disorder	Loma Linda University	Completed	No outcome recorded
—	NCT01104597 Background	Apr 2010 → Dec 2012	—	Northwell Health	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00586261 Comparator	Mar 2006 → Jan 2009	chronic kidney disease	Mayo Clinic	Terminated	No outcome recorded Stop: Enrollment
—	NCT00896311 Comparator	Mar 2003 → Oct 2006	pregnancy disorder	University of Calgary	Completed	No outcome recorded
—	NCT00901758 Comparator	Mar 2003 → Oct 2006	pregnancy disorder	University of Calgary	Completed	No outcome recorded
—	NCT00810381 Comparator	Jan → Jun 1999	glaucoma	Medical University of Vienna	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2024-02-22	Cosette Pharmaceuticals, Inc.	Regulatory Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity cosettepharma.com ↗ Cosette Pharmaceuticals, Inc. (“Cosette”) announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity.
2022-03-09	Zydus Lifesciences Limited	Regulatory Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets zyduslife.com ↗ Zydus Lifesciences Ltd. has received final approval from the USFDA to market Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg and 0.6mg (US RLD: Nitrostat Sublingual Tablets).
2019-05-08	NATCO Pharma Ltd.	Regulatory Natco’s marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets natcopharma.co.in ↗ Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg.

All press releases naming this drug 3 releases

Date	Issuer	Release
2024-02-22	Cosette Pharmaceuticals, Inc.	Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity cosettepharma.com ↗
2022-03-09	Zydus Lifesciences Limited	Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets zyduslife.com ↗
2019-05-08	NATCO Pharma Ltd.	Natco’s marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets natcopharma.co.in ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 177 sources stand behind the page.

Field	Value	Cited text
Known as	nitroglycerin	“Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the...” PMID 24010992 ↗ Sep 2013 130 “The ideal treatment would be a safe, inexpensive, quickly effective medication without significant side effects that could be administered without sedation or extensive...” NCT03305848 ↗ “milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline,...” NCT06301880 ↗ “A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953 ↗ “using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).” NCT00512759 ↗ “On the third day, under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.” NCT06172998 ↗ “Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732 ↗ “Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）” NCT03102502 ↗ “Application of nitroglycerin (glyceryl trinitrate) ointment with perianal administration is a widely used treatment for chronic anal fissure.” PMID 22810476 ↗ Aug 2012 “Nitroglycerin patches have been found to cause alleviation of pain especially when used in conjuction with morphine.” NCT00375362 ↗ “we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.” NCT05855954 ↗ Show 120 more sources
Known as	Anrecta	“The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)” NCT04320498 ↗
Known as	Glycerly Trinitrate	“Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal” NCT01811693 ↗
Known as	glyceryl trinitrate	“The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is...” NCT01811693 ↗ 34 “Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763 ↗ “0.4% Nitroglycerin ointment is an intra-anal formulation of nitroglycerin (glyceryl trinitrate) indicated for the treatment of chronic anal fissure pain.” PMID 16526822 ↗ 2006 “The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633 ↗ “Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985 ↗ “The Effect of Glyceryl Trinitrate (GTN) and Diamox on Cerebral Haemodynamics Judged With the Help of 3-Tesla MRI.” NCT00363571 ↗ “Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 ↗ Jul 2016 “self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day” NCT04320498 ↗ “glyceryl trinitrate， beta-Blocking agent，etc” NCT03478332 ↗ NCT03251599 ↗ NCT03787030 ↗ Show 24 more sources
Known as	GTN	“Eleven agents were used (nitroglycerin ointment (GTN), isosorbide dinitrate, Botulinum toxin (Botox), diltiazem, nifedipine (Calcium channel blockers or CCBs), hydrocortisone,...” PMID 17054170 ↗ Oct 2006 15 “The role of intravenous glyceryl trinitrate (GTN) therapy administered during cardiac surgery as a cardioprotective agent and whether it interferes with RIC cardioprotection is...” PMID 26412308 ↗ Sep 2015 “Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure” NCT05687669 ↗ “Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763 ↗ “The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633 ↗ “Nitrates, such as glyceryl trinitrate (GTN), are drugs that release NO (NO donors) and are widely used in the treatment and prevention of angina.” NCT00479908 ↗ “Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985 ↗ “Although the large Efficacy of Nitric Oxide in Stroke (ENOS) trial of transdermal glyceryl trinitrate (GTN) was neutral” PMID 26463698 ↗ Oct 2015 “Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks.” NCT06859554 ↗ “Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 ↗ Jul 2016 “Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor” PMID 32436761 ↗ May 2020 Show 5 more sources
Known as	GTO	“Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT03787030 ↗
Known as	IMX-150	“A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953 ↗
Known as	iNTG	“The use of inhaled nitroglycerin (iNTG) as an alternative pulmonary vasodilator.” PMID 38490779 ↗ Dec 2023
Known as	MQX-303	“The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in...” NCT00253331 ↗
Known as	MQX-503	“The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health...” NCT00577304 ↗ 5 “A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon” NCT00934427 ↗ “Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00266669 ↗ “Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00419419 ↗ “Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon” NCT00253331 ↗ “a fast acting topical formulation of Nitroglycerin, MQX-503” NCT00480753 ↗
Known as	MQX0503	“The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and...” NCT00577304 ↗
Known as	MXQ-503	“nitroglycerin 0.9 % (MXQ-503)” NCT00841594 ↗
Known as	Nitoglycerine-Glycerile Tinitrade	“topical 0.2% GTN cream (Nitoglycerine-Glycerile Tinitrade 0.2%, 30 gm; E.S.A.G Pharma Co., Cairo, Egypt).” NCT03528772 ↗
Known as	Nitroderm	“In the treatment group a nitroglycerin preparation (Nitroderm) was applied to the flap area.” PMID 21542401 ↗ Nov 2010
Known as	Nitroglycerin tablets	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270279 ↗ 1 NCT04270071 ↗
Known as	nitroglycerine	“Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine )” NCT04594629 ↗ 2 “Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy” NCT05741229 ↗ “Topical Formulation of Nitroglycerine, Vascana®” NCT02688270 ↗
Known as	Nitrostat	“Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732 ↗ 1 NCT01616485 ↗
Known as	NNG	“The objective was to evaluate the effect of nebulized nitroglycerin (NNG) in neonates with persistent pulmonary hypertension (PPHN).” PMID 40888971 ↗ Sep 2025
Known as	NTG	“RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US...” NCT01920074 ↗ 10 “OBJECTIVE: To determine whether uninterrupted administration of transdermal nitroglycerin (NTG) to induce nitrate cross-tolerance decreased the frequency or severity of...” PMID 37273224 ↗ Aug 2023 “Nitroglycerin (NTG) ointment is a potent topical vasodilator that increases local blood flow by dilating arteries and veins without altering the ratio of pre- to post-capillary...” NCT01608880 ↗ “Local nitroglycerin (NTG) was successfully used as a vasodilator to facilitate cannulation of the radial artery.” NCT04002544 ↗ “whether use of nitroglycerin (NTG) during CD has a protective effect.” PMID 27405400 ↗ Aug 2016 “nitroglycerin ointment (NTG) at 15 mg/day” NCT00252421 ↗ “glyceryl trinitrate (NTG, a NO donor)” NCT00419549 ↗ “Drug: Nitroglycerin (NTG)” NCT03357731 ↗ “Drug: Nitroglycerin (NTG)” NCT06682260 ↗ “Nitroglycerin (NTG)” NCT06637956 ↗ “Nitroglycerin (NTG)” NCT07083063 ↗
Known as	Perlinganit	“Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):” NCT00810381 ↗
Known as	RECTIV	“RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US...” NCT01920074 ↗
Known as	Recto-Relief Nitroglycerin Ointment	“application of local Nitroglycerin ointment 2% (Recto-Relief Nitroglycerin Ointment, 30 g) applied twice daily.” NCT05837403 ↗
Known as	Rectogesic	“Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT02700438 ↗ 3 “Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT03787030 ↗ “Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment” PMID 16526822 ↗ 2006 “Rectogesic® (glyceryl trinitrate 0.4% ointment)” NCT01132391 ↗
Known as	Vascana	“Vascana (0.9% nitroglycerin cream)” NCT02688270 ↗
Action	Restore	“Reversing nitric oxide deficiency by using nitroglycerin may prevent further bone loss.” NCT00043719 ↗
Route	Other	“intracoronary infusion of nitroglycerin” NCT00000503 ↗